ES
ESALF.US Eisai Co. Ltd
- Market cap
- USD 9.18B
- P/E
- 32.9x
- P/B
- 1.63x
- ROE
- 6.6%
- Dividend yield
- 3.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is ESALF.US undervalued?
Graham numberESALF.US trades 54.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eisai Co. Ltd fundamental analysis
No fundamental analysis for Eisai Co. Ltd yet.
Eisai Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eisai Co. Ltd
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over…
Full company profileEisai Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eisai Co. Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 539B | 600B | 643B | 696B | 646B | 756B | 744B | 742B | 789B | 831B | 942B |
| Gross Profit | 331B | 387B | 446B | 510B | 485B | 581B | 543B | 586B | 621B | 638B | 732B |
| Operating Income | 59.1B | 77.2B | 86.2B | 126B | 56.5B | 53.8B | 40.0B | 53.4B | 54.4B | 40.5B | 84.1B |
| EBITDA | 87.4B | 106B | 118B | 163B | 89.4B | 94.5B | 87.3B | 104B | 104B | 95.9B | 121B |
| Net Income | 39.4B | 51.8B | 63.4B | 122B | 41.9B | 48.0B | 55.4B | 42.4B | 46.4B | 38.8B | 59.9B |
| EPS | 137 | 181 | 221 | 425 | 146 | 167 | 193 | 148 | 164 | 138 | 212 |
| Balance Sheet | |||||||||||
| Total Assets | 1.03T | 1.05T | 1.07T | 1.06T | 1.09T | 1.24T | 1.26T | 1.39T | 1.39T | 1.46T | 1.53T |
| Total Liabilities | 428B | 435B | 420B | 360B | 362B | 468B | 441B | 495B | 521B | 527B | 604B |
| Shareholders' Equity | 585B | 594B | 628B | 678B | 703B | 749B | 800B | 876B | 841B | 905B | 901B |
| Cash & Short-term Investments | 230B | 289B | 294B | 256B | 249B | 310B | 267B | 305B | 266B | 247B | 319B |
| Total Debt | 213B | 173B | 139B | 89.9B | 89.9B | 143B | 126B | 159B | 188B | 187B | 256B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 75.9B | 150B | 104B | 103B | 73.9B | 118B | -1.77B | 56.0B | 30.1B | 61.7B | 60.2B |
| Capital Expenditure | 20.0B | 24.7B | 27.6B | 50.2B | 38.1B | 40.5B | 34.6B | 24.8B | 23.0B | 15.5B | 20.1B |
| Free Cash Flow | 55.9B | 125B | 76.1B | 52.6B | 35.7B | 77.1B | -36.3B | 31.2B | 7.15B | 46.3B | 40.1B |
| Ratios | |||||||||||
| ROE | 6.7% | 8.7% | 10.1% | 18.0% | 6.0% | 6.4% | 6.9% | 4.8% | 5.5% | 4.3% | 6.6% |
| ROA | 3.8% | 4.9% | 5.9% | 11.5% | 3.8% | 3.9% | 4.4% | 3.0% | 3.3% | 2.7% | 3.9% |
| Net Profit Margin | 7.3% | 8.6% | 9.9% | 17.5% | 6.5% | 6.3% | 7.4% | 5.7% | 5.9% | 4.7% | 6.4% |
| Debt to Equity | 0.37x | 0.29x | 0.22x | 0.13x | 0.13x | 0.19x | 0.16x | 0.18x | 0.22x | 0.21x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eisai Co. Ltd dividends
- Dividend yield
- 3.07%
- Forward dividend
- 1.00 USD
- Payout ratio
- 117.1%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 45.4B | 161 | 117.1% |
| 2025 | JPY 45.5B | 161 | 98.1% |
| 2024 | JPY 45.9B | 160 | 108.3% |
| 2023 | JPY 45.9B | 160 | 82.8% |
| 2022 | JPY 45.9B | 160 | 95.7% |
| 2021 | JPY 45.9B | 160 | 109.4% |
| 2020 | JPY 45.8B | 160 | 37.7% |
| 2019 | JPY 43.0B | 150 | 67.8% |
| 2018 | JPY 42.9B | 150 | 82.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 21:20 on Mar 26, 1996.
Who owns Eisai Co. Ltd
- Insiders 2.06%
- Institutions 56.07%
- Public & others 41.88%
- Shares outstanding 282M
- Free float 282M
Eisai Co. Ltd company profile
- Company name
- Eisai Co. Ltd
- Ticker
- ESALF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,543
- Fiscal year end
- March
- Address
- 4-6-10 Koishikawa, Tokyo, Japan, 112-8088
- Phone
- 81 3 3817 3700
- Website
- eisai.co.jp
About Eisai Co. Ltd
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Eisai Co. Ltd management
10- Mr. Haruo NaitoCEO, Representative Corporate Officer & Director · born 1947
- Mr. Keisuke NaitoRepresentative Corporate Officer, EVP, COO & Chief Growth Officer · born 1988
- Mr. Terushige IikeExecutive VP, Rep. Corporate Officer & Chief Business Officer · born 1963
- Dr. Lynn D. Kramer FAAN, M.D.VP & Chief Clinical Officer · born 1950
- Ms. Yanhui FengSenior Vice President · born 1972
- Mr. Takuya OyamaVice President, Chief Financial Officer & Chief IR Officer · born 1977
- Ms. Akiko NakahamaVice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology · born 1968
- Makoto HoketsuVP & Chief Information Officer · born 1968
- Dr. Katsutoshi IdoVP, Chief Scientific Officer & Head of DHBL Discoverry · born 1978
- Mr. Teruyuki MasakaVP and Chief HR Officer, Corporate Communications, Sustainability & General Affairs · born 1978